Profile data is unavailable for this security.
About the company
Kangmei Pharmaceutical Co Ltd is a China-based company mainly engaged in the production and sale of pharmaceutical products. The Company's main products include Chinese herbal medicines, Chinese patent medicines, chemical medicines, health foods and foods. Chinese herbal medicines include Panax notoginseng powder, American ginseng, Kangmei lily, Kangmei salvia miltiorrhiza, and others. The main chemical medicine products are acetaminophen powder and norfloxacin capsules. The main foods are chrysanthemum tea, solid beverages, ginseng tablets, and red ginseng extract. The Company is also engaged in medical equipment, property leasing and sales and other services. The Company mainly conducts business in the domestic market.
- Revenue in CNY (TTM)5.28bn
- Net income in CNY16.64m
- Incorporated1997
- Employees4.23k
- LocationKangmei Pharmaceutical Co LtdTaike Road, Xiameilin, Futian DistrictSHENZHEN 518000ChinaCHN
- Phone+86 75 533187777
- Fax+86 75 586275777
- Websitehttp://www.kangmei.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tasly Pharmaceutical Group Co Ltd | 8.35bn | 1.10bn | 21.92bn | 10.96k | 19.96 | 1.78 | -- | 2.63 | 0.7348 | 0.7348 | 5.59 | 8.24 | 0.525 | 1.83 | 7.50 | 761,658.60 | 6.44 | 5.86 | 7.91 | 7.26 | 65.70 | 58.62 | 12.26 | 10.61 | 3.12 | -- | 0.0642 | 56.80 | -2.03 | -14.86 | -10.78 | -0.9327 | -5.02 | 9.94 |
| Bloomage Biotechnology Corp Ltd | 4.66bn | 64.62m | 22.76bn | 4.44k | 338.86 | 3.20 | -- | 4.88 | 0.1394 | 0.1394 | 9.59 | 14.76 | 0.5431 | 1.12 | 8.61 | 1,048,475.00 | 0.719 | 8.43 | 0.827 | 9.97 | 70.71 | 75.45 | 1.32 | 12.34 | 1.42 | 40.02 | 0.0317 | 30.32 | -11.61 | 23.29 | -70.59 | -21.53 | 9.89 | -21.54 |
| Zhejiang Huahai Pharmaceutical Co., Ltd. | 8.71bn | 468.07m | 23.52bn | 9.07k | 48.25 | 2.47 | -- | 2.70 | 0.3256 | 0.3256 | 6.00 | 6.35 | 0.4279 | 0.9611 | 3.17 | 960,689.80 | 2.18 | 5.67 | 3.15 | 7.93 | 59.76 | 60.79 | 5.10 | 11.66 | 0.7399 | 8.95 | 0.4519 | 31.74 | 14.91 | 12.12 | 34.74 | 14.46 | 18.47 | 6.58 |
| Suzhou Zelgen Biopharmaceuticals Co Ltd | 742.28m | -133.34m | 24.99bn | 910.00 | -- | 21.75 | -- | 33.67 | -0.5038 | -0.5038 | 2.80 | 4.34 | 0.2482 | 0.446 | 4.77 | 815,689.40 | -4.56 | -17.15 | -8.23 | -25.89 | 89.95 | 93.14 | -18.36 | -118.33 | 1.72 | -- | 0.4949 | -- | 37.91 | -- | 50.52 | -- | 44.66 | -- |
| Hubei Jumpcan Pharmaceutical Co Ltd | 6.14bn | 1.65bn | 25.04bn | 5.03k | 15.11 | 1.81 | -- | 4.08 | 1.80 | 1.80 | 6.69 | 15.02 | 0.3543 | 2.99 | 3.59 | 1,222,407.00 | 9.53 | 15.19 | 11.67 | 19.57 | 75.44 | 81.73 | 26.91 | 26.02 | 5.18 | -- | 0.0437 | 46.90 | -16.96 | 2.93 | -10.32 | 9.30 | -20.43 | 11.19 |
| Kangmei Pharmaceutical Co Ltd | 5.28bn | 16.64m | 26.14bn | 4.23k | 1,643.48 | 3.64 | -- | 4.95 | 0.0012 | 0.0012 | 0.3973 | 0.5197 | 0.3785 | 1.64 | 2.23 | 1,246,204.00 | 0.1368 | -21.82 | 0.2232 | -42.17 | 17.12 | -92.73 | 0.3614 | -108.18 | 0.7875 | -- | 0.0162 | -- | 6.47 | -14.63 | -91.64 | -- | -33.46 | -- |
| Tianjin Pharmcetl Da Ren Tang Grp Cp Ltd | 5.37bn | 3.58bn | 29.37bn | 3.84k | 9.29 | 3.69 | -- | 5.47 | 4.65 | 4.65 | 6.98 | 11.70 | 0.4758 | 1.35 | 3.16 | 1,399,130.00 | 31.64 | 11.74 | 45.06 | 16.76 | 64.27 | 42.04 | 66.50 | 14.81 | 2.33 | -- | 0.0056 | 54.04 | -11.14 | 0.8791 | 125.94 | 28.94 | -10.54 | 33.67 |
| Xiamen Amoytop Biotech Co Ltd | 3.34bn | 939.58m | 29.55bn | 2.42k | 31.34 | 9.79 | -- | 8.84 | 2.31 | 2.31 | 8.22 | 7.40 | 1.03 | 0.8127 | 4.99 | 1,379,284.00 | 29.05 | 22.72 | 33.93 | 26.54 | 92.37 | 91.62 | 28.11 | 23.51 | 3.20 | -- | 0.0448 | 28.80 | 34.13 | 31.02 | 49.00 | 66.70 | 41.17 | 90.06 |
Data as of Feb 13 2026. Currency figures normalised to Kangmei Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
0.30%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Feb 2026 | 36.43m | 0.27% |
| Vanguard Fiduciary Trust Co.as of 30 Nov 2025 | 1.28m | 0.01% |
| Vanguard Asset Management Ltd.as of 31 Dec 2025 | 746.20k | 0.01% |
| China Fund Management Co., Ltd.as of 30 Jun 2025 | 688.00k | 0.01% |
| Charles Schwab Investment Management, Inc.as of 05 Feb 2026 | 622.80k | 0.01% |
| State Street Global Advisors Ltd.as of 31 Dec 2025 | 571.31k | 0.00% |
| BOCI-Prudential Asset Management Ltd.as of 30 Sep 2025 | 404.50k | 0.00% |
| Assenagon Asset Management SA (Germany)as of 29 Dec 2025 | 315.85k | 0.00% |
| Goldman Sachs Asset Management LPas of 06 Feb 2026 | 238.54k | 0.00% |
| ICBC UBS Asset Management (International) Co. Ltd.as of 30 Jun 2025 | 138.30k | 0.00% |
More ▼
Data from 30 Jun 2025 - 12 Feb 2026Source: FactSet Research Systems Inc.
